Tags

Type your tag names separated by a space and hit enter

Use of Japanese encephalitis vaccine in children: recommendations of the advisory committee on immunization practices, 2013.
MMWR Morb Mortal Wkly Rep 2013; 62(45):898-900MM

Abstract

On June 19, 2013, the Advisory Committee on Immunization Practices (ACIP) voted to extend existing recommendations for use of inactivated Vero cell culture-derived Japanese encephalitis (JE) vaccine (JE-VC) (Ixiaro, Intercell Biomedical) to include children aged 2 months through 16 years. The ACIP JE Vaccine Workgroup reviewed the epidemiology of JE in travelers and evaluated published and unpublished data on JE-VC immunogenicity and safety in adults and children. The evidence for benefits and risks associated with JE-VC vaccination of children was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework. This report summarizes the evidence considered by ACIP and outlines the recommendations for use of JE-VC in children traveling to JE-endemic countries.

Links

  • PMC Free PDF
    • Publisher Full Text
    ncbi.nlm.nih.gov
    cdc.gov

    Authors

    Centers for Disease Control and Prevention (CDC)
    No affiliation info available

    MeSH

    AdolescentAdvisory CommitteesChildChild, PreschoolEncephalitis, JapaneseHumansImmunization ScheduleInfantJapanese Encephalitis VaccinesRandomized Controlled Trials as TopicRisk AssessmentTravelUnited StatesVaccines, Inactivated

    Pub Type(s)

    Journal Article
    Practice Guideline

    Language

    eng

    PubMed ID

    24226626

    Citation

    Centers for Disease Control and Prevention (CDC). "Use of Japanese Encephalitis Vaccine in Children: Recommendations of the Advisory Committee On Immunization Practices, 2013." MMWR. Morbidity and Mortality Weekly Report, vol. 62, no. 45, 2013, pp. 898-900.
    Centers for Disease Control and Prevention (CDC). Use of Japanese encephalitis vaccine in children: recommendations of the advisory committee on immunization practices, 2013. MMWR Morb Mortal Wkly Rep. 2013;62(45):898-900.
    Centers for Disease Control and Prevention (CDC). (2013). Use of Japanese encephalitis vaccine in children: recommendations of the advisory committee on immunization practices, 2013. MMWR. Morbidity and Mortality Weekly Report, 62(45), pp. 898-900.
    Centers for Disease Control and Prevention (CDC). Use of Japanese Encephalitis Vaccine in Children: Recommendations of the Advisory Committee On Immunization Practices, 2013. MMWR Morb Mortal Wkly Rep. 2013 Nov 15;62(45):898-900. PubMed PMID: 24226626.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Use of Japanese encephalitis vaccine in children: recommendations of the advisory committee on immunization practices, 2013. A1 - ,, PY - 2013/11/15/entrez PY - 2013/11/15/pubmed PY - 2014/1/7/medline SP - 898 EP - 900 JF - MMWR. Morbidity and mortality weekly report JO - MMWR Morb. Mortal. Wkly. Rep. VL - 62 IS - 45 N2 - On June 19, 2013, the Advisory Committee on Immunization Practices (ACIP) voted to extend existing recommendations for use of inactivated Vero cell culture-derived Japanese encephalitis (JE) vaccine (JE-VC) (Ixiaro, Intercell Biomedical) to include children aged 2 months through 16 years. The ACIP JE Vaccine Workgroup reviewed the epidemiology of JE in travelers and evaluated published and unpublished data on JE-VC immunogenicity and safety in adults and children. The evidence for benefits and risks associated with JE-VC vaccination of children was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework. This report summarizes the evidence considered by ACIP and outlines the recommendations for use of JE-VC in children traveling to JE-endemic countries. SN - 1545-861X UR - https://www.unboundmedicine.com/medline/citation/24226626/full_citation L2 - https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6245a3.htm DB - PRIME DP - Unbound Medicine ER -